Quantcast
Home > Quotes > ARRY
x
ARRY

Array BioPharma Inc. Common Stock (ARRY) Quote & Summary Data

$15.15
*  
0.31
2.01%
Get ARRY Alerts
*Delayed - data as of Oct. 19, 2018  -  Find a broker to begin trading ARRY now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 14.94 / $ 15.35
Today's High / Low
$ 15.6569 / $ 15.01
Share Volume
2,326,220
50 Day Avg. Daily Volume
2,381,067
Previous Close
$ 15.46
52 Week High / Low
$ 20.21 / $ 9.98
Market Cap
3,225,763,588
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
2,326,220
50 Day Avg. Daily Volume:
2,381,067

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.75

Trading Range

The current last sale of $15.15 is 51.80% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 15.6569 $ 20.21
 Low: $ 15.01 $ 9.98

ETFs with ARRY as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
1.46% SPDR Series Trust SPDR S&P Biotech ETF (XBI) -4.93 (-5.33%)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.

Company Description (as filed with the SEC)

We are a fully-integrated, biopharmaceutical company focused on the discovery, development and commercialization of transformative and well-tolerated targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. We market in the United States BRAFTOVITM (encorafenib) capsules in combination with MEKTOVI® (binimetinib) tablets for the treatment of patients with unresectable or metastatic melanoma with a BRAFV600E or BRAFV600K mutation. Our lead clinical programs, encorafenib and binimetinib, are being investigated in over 30 clinical trials across a number of solid tumor indications, including a Phase 3 trial in BRAF-mutant colorectal cancer (CRC).  ... More ...  


Risk Grade

Where does ARRY fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 15.49
Open Date:
Oct. 19, 2018
Close Price:
$ 15.15
Close Date:
Oct. 19, 2018

Consensus Recommendation

Analyst Info